{"id":"https://openalex.org/W2018164189","doi":"https://doi.org/10.1111/j.1365-2125.2009.03400.x","title":"Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example","display_name":"Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example","publication_year":2009,"publication_date":"2009-02-26","ids":{"openalex":"https://openalex.org/W2018164189","doi":"https://doi.org/10.1111/j.1365-2125.2009.03400.x","mag":"2018164189","pmid":"https://pubmed.ncbi.nlm.nih.gov/19552751","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2686073"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2125.2009.03400.x","doi":"https://doi.org/10.1111/j.1365-2125.2009.03400.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.2009.03400.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2009.03400.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2009.03400.x","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065076079","display_name":"Florence P. A. M. van Hunsel","orcid":"https://orcid.org/0000-0001-8965-3224","observed_orcids":["https://orcid.org/0000-0001-8965-3224"]},"institutions":[{"id":"https://openalex.org/I169381384","display_name":"University of Groningen","ror":"https://ror.org/012p63287","country_code":"NL","type":"education","lineage":["https://openalex.org/I169381384"]},{"id":"https://openalex.org/I4210139651","display_name":"Netherlands Pharmacovigilance Centre Lareb","ror":"https://ror.org/04fp8ns78","country_code":"NL","type":"facility","lineage":["https://openalex.org/I4210139651"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Florence Van Hunsel","raw_affiliation_strings":["Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands. vanhunsel@lareb.nl","Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch and","University of Groningen, Department of Pharmacy: Pharmacotherapy and Pharmaceutical Care, Groningen, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands. vanhunsel@lareb.nl","institution_ids":["https://openalex.org/I4210139651"]},{"raw_affiliation_string":"Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch and","institution_ids":["https://openalex.org/I4210139651"]},{"raw_affiliation_string":"University of Groningen, Department of Pharmacy: Pharmacotherapy and Pharmaceutical Care, Groningen, the Netherlands","institution_ids":["https://openalex.org/I169381384"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016526464","display_name":"Anneke Passier","orcid":"https://orcid.org/0000-0001-5594-6360","observed_orcids":["https://orcid.org/0000-0001-5594-6360"]},"institutions":[{"id":"https://openalex.org/I4210139651","display_name":"Netherlands Pharmacovigilance Centre Lareb","ror":"https://ror.org/04fp8ns78","country_code":"NL","type":"facility","lineage":["https://openalex.org/I4210139651"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Anneke Passier","raw_affiliation_strings":["Netherlands Pharmacovigilance Centre Lareb, \u2018s-Hertogenbosch and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Netherlands Pharmacovigilance Centre Lareb, \u2018s-Hertogenbosch and","institution_ids":["https://openalex.org/I4210139651"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5020000643","display_name":"Kees van Grootheest","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I169381384","display_name":"University of Groningen","ror":"https://ror.org/012p63287","country_code":"NL","type":"education","lineage":["https://openalex.org/I169381384"]},{"id":"https://openalex.org/I4210139651","display_name":"Netherlands Pharmacovigilance Centre Lareb","ror":"https://ror.org/04fp8ns78","country_code":"NL","type":"facility","lineage":["https://openalex.org/I4210139651"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Kees Van Grootheest","raw_affiliation_strings":["Netherlands Pharmacovigilance Centre Lareb, \u2018s-Hertogenbosch and","University of Groningen, Department of Pharmacy: Pharmacotherapy and Pharmaceutical Care, Groningen, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Netherlands Pharmacovigilance Centre Lareb, \u2018s-Hertogenbosch and","institution_ids":["https://openalex.org/I4210139651"]},{"raw_affiliation_string":"University of Groningen, Department of Pharmacy: Pharmacotherapy and Pharmaceutical Care, Groningen, the Netherlands","institution_ids":["https://openalex.org/I169381384"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4780,"currency":"USD","value_usd":4780},"apc_paid":null,"fwci":5.5212,"has_fulltext":false,"cited_by_count":87,"citation_normalized_percentile":{"value":0.94990278,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":99},"biblio":{"volume":"67","issue":"5","first_page":"558","last_page":"564"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11649","display_name":"Pharmaceutical industry and healthcare","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2910","display_name":"Issues, ethics and legal aspects"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10902","display_name":"Complementary and Alternative Medicine Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2707","display_name":"Complementary and alternative medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.8999999761581421},{"id":"https://openalex.org/keywords/patient-reporting","display_name":"patient reporting","score":0.8700000047683716},{"id":"https://openalex.org/keywords/media-attention","display_name":"media attention","score":0.859000027179718},{"id":"https://openalex.org/keywords/television-programmes","display_name":"television programmes","score":0.6940000057220459},{"id":"https://openalex.org/keywords/statins","display_name":"statins","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.8930000066757202},{"id":"https://openalex.org/keywords/spontaneous-reporting","display_name":"spontaneous reporting","score":0.7450000047683716},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.921999990940094},{"id":"https://openalex.org/keywords/patient-concerns","display_name":"patient concerns","score":0.34700000286102295}],"concepts":[{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.9141397476196289},{"id":"https://openalex.org/C2776650110","wikidata":"https://www.wikidata.org/wiki/Q12891156","display_name":"Seriousness","level":2,"score":0.8464165329933167},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.7648569345474243},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7526437044143677},{"id":"https://openalex.org/C2780542314","wikidata":"https://www.wikidata.org/wiki/Q45959","display_name":"Adverse drug reaction","level":3,"score":0.5764071345329285},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.5761007070541382},{"id":"https://openalex.org/C3019806175","wikidata":"https://www.wikidata.org/wiki/Q11974939","display_name":"Health professionals","level":3,"score":0.5677669048309326},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.47064918279647827},{"id":"https://openalex.org/C2993432071","wikidata":"https://www.wikidata.org/wiki/Q45959","display_name":"Drug reaction","level":3,"score":0.4431096911430359},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.37119561433792114},{"id":"https://openalex.org/C545542383","wikidata":"https://www.wikidata.org/wiki/Q2751242","display_name":"Medical emergency","level":1,"score":0.3234969973564148},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.18443775177001953},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.17227068543434143},{"id":"https://openalex.org/C50522688","wikidata":"https://www.wikidata.org/wiki/Q189833","display_name":"Economic growth","level":1,"score":0.0},{"id":"https://openalex.org/C199539241","wikidata":"https://www.wikidata.org/wiki/Q7748","display_name":"Law","level":1,"score":0.0},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D001291","descriptor_name":"Attitude of Health Personnel","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003146","descriptor_name":"Communications Media","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005069","descriptor_name":"Evaluation Studies as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006331","descriptor_name":"Heart Diseases","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007722","descriptor_name":"Health Knowledge, Attitudes, Practice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009426","descriptor_name":"Netherlands","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010817","descriptor_name":"Physician-Patient Relations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016903","descriptor_name":"Drug Monitoring","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016907","descriptor_name":"Adverse Drug Reaction Reporting Systems","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":true},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D064420","descriptor_name":"Drug-Related Side Effects and Adverse Reactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":5,"locations":[{"id":"doi:10.1111/j.1365-2125.2009.03400.x","doi":"https://doi.org/10.1111/j.1365-2125.2009.03400.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.2009.03400.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2009.03400.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:2686073","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2686073","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Clin Pharmacol","raw_type":"Text"},{"id":"pmid:19552751","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19552751","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Comparative Study"},{"id":"pmh:oai:pure.rug.nl:openaire_cris_publications/20fa57f2-bebe-4c65-b242-95a68b44dae2","doi":null,"is_oa":false,"landing_page_url":"https://hdl.handle.net/11370/20fa57f2-bebe-4c65-b242-95a68b44dae2","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"van Hunsel, F, Passier, A & van Grootheest, K 2009, 'Comparing patients' and healthcare professionals' ADR reports after media attention : The broadcast of a Dutch television programme about the benefits and risks of statins as an example', British Journal of Clinical Pharmacology, vol. 67, no. 5, pp. 558-564. https://doi.org/10.1111/j.1365-2125.2009.03400.x","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:rug:oai:pure.rug.nl:publications/20fa57f2-bebe-4c65-b242-95a68b44dae2","doi":null,"is_oa":false,"landing_page_url":"https://research.rug.nl/en/publications/20fa57f2-bebe-4c65-b242-95a68b44dae2","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"British Journal of Clinical Pharmacology, 67(5), 558 - 564. Wiley","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1111/j.1365-2125.2009.03400.x","doi":"https://doi.org/10.1111/j.1365-2125.2009.03400.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.2009.03400.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2009.03400.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2018164189.pdf"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W180335173","https://openalex.org/W1418851693","https://openalex.org/W1467903879","https://openalex.org/W1544133109","https://openalex.org/W1939080369","https://openalex.org/W1975929460","https://openalex.org/W1978632251","https://openalex.org/W1987244403","https://openalex.org/W1990684695","https://openalex.org/W1994043460","https://openalex.org/W2058816028","https://openalex.org/W2062307183","https://openalex.org/W2083297806","https://openalex.org/W2085752173","https://openalex.org/W2090673567","https://openalex.org/W2091266443","https://openalex.org/W2098897740","https://openalex.org/W2121066811","https://openalex.org/W2151072354","https://openalex.org/W2155701005","https://openalex.org/W2418801225"],"related_works":["https://openalex.org/W2151072354","https://openalex.org/W2110931670","https://openalex.org/W2605264062","https://openalex.org/W2505543853","https://openalex.org/W1584926918","https://openalex.org/W2058945689","https://openalex.org/W1994043460","https://openalex.org/W2888335253","https://openalex.org/W1978687394","https://openalex.org/W7223090536"],"abstract_inverted_index":{"WHAT":[0,49],"IS":[1],"ALREADY":[2],"KNOWN":[3],"ABOUT":[4],"THIS":[5,50],"SUBJECT":[6],"\u2022":[7,20,31,53,67],"More":[8],"and":[9,28,82,99,114,122,127,148,157,163,175,191,222,231,267,283,319],"more":[10,237],"countries":[11],"accept":[12],"patient":[13,34,155,205,221],"reporting":[14,18,35,55,58,187,206,212,285],"in":[15,184,204,211,226,253,328],"their":[16,269],"spontaneous":[17],"systems.":[19],"Media":[21],"exposure":[22],"about":[23,65,111,322],"drugs":[24],"can":[25,290],"influence":[26],"patients":[27,98],"health":[29,60,87,100,128,214,223,240,303],"professionals.":[30,215,241,277],"Evaluation":[32],"of":[33,36,46,105,116,131,154,160,165,177,207,228,299,314],"adverse":[37,92,323],"drug":[38,93,173,232,251,281],"reactions":[39,324],"is":[40,245],"needed":[41],"to":[42,86,133,201,302,330],"provide":[43,70,291],"further":[44],"evidence":[45],"its":[47],"benefits.":[48],"STUDY":[51],"ADDS":[52],"Patient":[54,68,288],"compared":[56],"with":[57],"by":[59,139,213,275,286],"professionals":[61,101],"after":[62,102],"media":[63],"attention":[64,199,279],"statins.":[66,117,134],"reports":[69,96,130,136,162,225,289,329],"additional":[71,292],"insight":[72],"into":[73,311],"impact":[74,313],"on":[75,125,316],"daily":[76,317],"life,":[77,318],"the":[78,103,112,140,166,178,185,229,312],"patient\u2013health":[79],"professional":[80,224,304],"relationship":[81],"general":[83],"worries":[84],"next":[85,301],"professionals'":[88,129],"reports.":[89,256,305],"AIMSTo":[90],"compare":[91],"reaction":[94],"(ADR)":[95],"from":[97],"broadcast":[104],"a":[106,120,192,202,248,296],"Dutch":[107],"television":[108],"consumer":[109],"programme":[110,244],"benefits":[113],"risks":[115],"METHODSWe":[118],"performed":[119],"quantitative":[121],"qualitative":[123],"analysis":[124,194,307],"patients'":[126,320],"ADRs":[132,208,230],"These":[135],"were":[137,189,217,271],"received":[138,161],"Netherlands":[141],"Pharmacovigilance":[142],"Centre":[143],"Lareb":[144],"between":[145,220],"March":[146],"2007":[147],"August":[149],"2007.":[150],"Quantitative":[151],"data":[152],"consisted":[153],"age":[156],"gender,":[158],"number":[159],"characteristics":[164],"report":[167],"(most":[168],"frequently":[169],"reported":[170,179,235],"ADRs,":[171],"seriousness,":[172],"discontinuation":[174,252],"outcome":[176],"reaction).":[180],"Open":[181],"text":[182],"fields":[183],"ADR":[186,284],"form":[188],"categorized":[190],"content":[193],"was":[195],"carried":[196],"out.":[197],"RESULTSMedia":[198],"led":[200],"peak":[203],"but":[209],"not":[210,263,272],"There":[216],"no":[218],"differences":[219],"seriousness":[227],"cessation.":[233],"Patients":[234,257],"nonrecovery":[236],"often":[238,258],"than":[239],"The":[242],"TV":[243],"mentioned":[246],"as":[247],"reason":[249],"for":[250],"almost":[254],"30":[255],"felt":[259],"that":[260,268],"they":[261],"did":[262],"receive":[264],"sufficient":[265],"information":[266,300],"concerns":[270,321],"adequately":[273],"addressed":[274],"healthcare":[276],"CONCLUSIONSMedia":[278],"affects":[280],"use":[282],"patients.":[287],"information,":[293],"making":[294],"them":[295],"useful":[297],"source":[298],"Content":[306],"provides":[308],"vital":[309],"insights":[310],"statins":[315],"should":[325],"be":[326],"recognized":[327],"national":[331],"pharmacovigilance":[332],"centres.":[333]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":5},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":9},{"year":2016,"cited_by_count":10},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}